"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 624-631

  Davis, Alison ^a   Tinker, Anna V ^b   Friedlander, Michael ^c  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Genotype; Histotype; Ovarian cancer; Platinum resistant; Treatment

Indexed keywords

9 AMINOCAMPTOTHECIN; ALTRETAMINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; COSITECAN; CYCLOSPORIN A; DASATINIB; DOCETAXEL; ENZASTAURIN; GEFITINIB; GEMCITABINE; IMATINIB; IROFULVEN; LAPATINIB; LEDOXANTRONE; MIFEPRISTONE; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEMETREXED; SORAFENIB; TEMSIROLIMUS; TRABECTEDIN; UNINDEXED DRUG; VALSPODAR; VORINOSTAT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; ENDOMETRIOID CARCINOMA; EXCISION REPAIR; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; GENOTYPE; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH GRADE SEROUS CARCINOMA; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; LOW GRADE SEROUS CARCINOMA; MISMATCH REPAIR; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLATINUM RESISTANT OVARIAN CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; SOMATIC MUTATION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

GENOTYPE; HISTOTYPE; OVARIAN CANCER; PLATINUM RESISTANT; TREATMENT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS;

EID: 84901674128     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.038     Document Type: Review

References (70)

1. GLOBOCAN 2008 v1.2 Cancer Incidence and Mortality Worldwide [Internet] 2010
2. M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 3 1991 389 393
3. P.G. Rose, N. Fusco, L. Fluellen, and M. Rodriguez Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma J Clin Oncol 16 4 1998 1494 1497
4. G. Balbi, L. Di Prisco, R. Musone, A. Menditto, E. Cassese, and C. Balbi et al. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma Eur J Gynaecol Oncol 23 4 2002 347 349
5. A.V. Hoekstra, J.A. Hurteau, C.V. Kirschner, and G.C. Rodriguez The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer Gynecol Oncol 115 3 2009 377 381
6. G. Blackledge, F. Lawton, C. Redman, and K. Kelly Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 4 1989 650 653
7. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 2 1990 207 211
8. T.I. Goonewardene, M.R. Hall, and G.J. Rustin Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations Lancet Oncol 8 9 2007 813 821
9. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 10 1998 3345 3352
10. M. Friedlander, E. Trimble, A. Tinker, D. Alberts, E. Avall-Lundqvist, and M. Brady et al. Clinical trials in recurrent ovarian cancer Int J Gynecol Cancer 21 4 2011 771 775
11. H.J. Mackay, M.F. Brady, A.M. Oza, A. Reuss, E. Pujade-Lauraine, and A.M. Swart et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer Int J Gynecol Cancer 20 6 2010 945 952
12. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, and J. George et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J Clin Oncol 30 21 2012 2654 2663
13. K.A. Schrader, J. Hurlburt, S.E. Kalloger, S. Hansford, S. Young, and D.G. Huntsman et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy Obstet Gynecol 120 2 Pt 1 2012 235 240
14. Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, and U. Beller et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 2 2002 463 466
15. I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi, S.A. Narod, and B.Y. Karlan Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 9 2003 2187 2195
16. D.S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, and S. Shanley et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 34 2008 5530 5536
17. P.M. Vencken, M. Kriege, D. Hoogwerf, S. Beugelink, M.E. van der Burg, and M.J. Hooning et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Ann Oncol 22 6 2011 1346 1352
18. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, and S. Narod et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Cancer Res 60 19 2000 5329 5333
19. M. Esteller, J.M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, and E. Lerma et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 7 2000 564 569
20. K.A. Foster, P. Harrington, J. Kerr, P. Russell, R.A. DiCioccio, and I.V. Scott et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer Cancer Res 56 16 1996 3622 3625
21. J.L. Hilton, J.P. Geisler, J.A. Rathe, M.A. Hattermann-Zogg, B. DeYoung, and R.E. Buller Inactivation of BRCA1 and BRCA2 in ovarian cancer J Natl Cancer Inst 94 18 2002 1396 1406
22. L. Hughes-Davies, D. Huntsman, M. Ruas, F. Fuks, J. Bye, and S.F. Chin et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer Cell 115 5 2003 523 535
23. T. Taniguchi, M. Tischkowitz, N. Ameziane, S.V. Hodgson, C.G. Mathew, and H. Joenje et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 9 5 2003 568 574
24. N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, and S. Swift et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 16 2006 8109 8115
25. A.D. D'Andrea The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers Cell Cycle 2 4 2003 290 292
26. J.M. Teodoridis, J. Hall, S. Marsh, H.D. Kannall, C. Smyth, and J. Curto et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer Cancer Res 65 19 2005 8961 8967
27. P.A. Konstantinopoulos, D. Spentzos, B.Y. Karlan, T. Taniguchi, E. Fountzilas, and N. Francoeur et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J Clin Oncol 28 22 2010 3555 3561
28. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
29. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, and O. Kepp et al. Molecular mechanisms of cisplatin resistance Oncogene 31 15 2012 1869 1883
30. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 47 2003 7265 7279
31. G. Tapia, and I. Diaz-Padilla Molecular Mechanisms of Platinum resistance in Ovarian cancer 2013
32. M. Dabholkar, J. Vionnet, F. Bostick-Bruton, J.J. Yu, and E. Reed Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 2 1994 703 708
33. J. Helleman, I.L. van Staveren, W.N. Dinjens, P.F. van Kuijk, K. Ritstier, and P.C. Ewing et al. Mismatch repair and treatment resistance in ovarian cancer BMC Cancer 6 2006 201
34. E.M. Swisher, W. Sakai, B.Y. Karlan, K. Wurz, N. Urban, and T. Taniguchi Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 8 2008 2581 2586
35. W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, J. Higgins, and C. Friedman et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 7182 2008 1116 1120
36. H. Zahreddine, and K.L. Borden Mechanisms and insights into drug resistance in cancer Front Pharmacol 4 2013 28
37. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 4 2005 275 284
38. C. Massard, E. Deutsch, and J.C. Soria Tumour stem cell-targeted treatment: elimination or differentiation Ann Oncol 17 11 2006 1620 1624
39. M. Mimeault, R. Hauke, P.P. Mehta, and S.K. Batra Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers J Cell Mol Med 11 5 2007 981 1011
40. S. Ma, T.K. Lee, B.J. Zheng, K.W. Chan, and X.Y. Guan CD133 + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway Oncogene 27 12 2008 1749 1758
41. P.C. Hermann, S.L. Huber, T. Herrler, A. Aicher, J.W. Ellwart, and M. Guba et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Cell Stem Cell 1 3 2007 313 323
42. J. Helleman, M.P. Jansen, C. Burger, M.E. van der Burg, and E.M. Berns Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs Int J Biochem Cell Biol 42 1 2010 25 30
43. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, and S. Lade et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin Cancer Res 14 16 2008 5198 5208
44. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012 883 892
45. A. Bashashati, G. Ha, A. Tone, J. Ding, L.M. Prentice, and A. Roth et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling J Pathol 231 1 2013 21 34
46. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 33 2007 5180 5186
47. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 33 2007 5165 5171
48. J.C. Chura, K. Van Iseghem, L.S. Downs Jr., L.F. Carson, and P.L. Judson Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Gynecol Oncol 107 2 2007 326 330
49. A. Sanchez-Munoz, C. Mendiola, E. Perez-Ruiz, C.A. Rodriguez-Sanchez, J.M. Jurado, and L. Alonso-Carrion et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Oncology 79 1-2 2010 98 104
50. M. Markman Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer Gynecol Oncol 124 1 2012 171 [author reply -2]
51. P. Witteveen, A. Lortholary, T. Fehm, A. Poveda, A. Reuss, and H. Havsteen et al. FInal overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OS). European Cancer Congress LBA 5 Eur J Cancer 49 Suppl. 3 2013 S3
52. B.J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, and D.S. Bae et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoeitin 1 and 2 inhibitor, trabananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. European Cancer Congress LBA 41 Eur J Cancer 49 Suppl. 2 2013 S18
53. G.J. Rustin, M.E. van der Burg, C.L. Griffin, D. Guthrie, A. Lamont, and G.C. Jayson et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 9747 2010 1155 1163
54. R.W. Holloway, R.S. Mehta, N.J. Finkler, K.T. Li, C.E. McLaren, and R.J. Parker et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol Oncol 87 1 2002 8 16
55. H. Gallion, W.A. Christopherson, R.L. Coleman, L. DeMars, T. Herzog, and S. Hosford et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay Int J Gynecol Cancer 16 1 2006 194 201
56. T.J. Herzog, T.C. Krivak, A.N. Fader, and R.L. Coleman Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer Am J Obstet Gynecol 203 1 2010 [68 e1-6]
57. T. Rutherford, J. Orr Jr., E. Grendys Jr., R. Edwards, T.C. Krivak, and R. Holloway et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer Gynecol Oncol 131 1 2013 276
58. P.J. Hoskins, and N. Le Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer Gynecol Oncol 97 3 2005 862 869
59. C. Doyle, M. Crump, M. Pintilie, and A.M. Oza Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer J Clin Oncol 19 5 2001 1266 1274
60. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J Clin Oncol 15 6 1997 2183 2193
61. P. Rosenberg, H. Andersson, K. Boman, M. Ridderheim, B. Sorbe, and U. Puistola et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 5 2002 418 424
62. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 14 2001 3312 3322
63. A. Buda, I. Floriani, R. Rossi, N. Colombo, V. Torri, and P.F. Conte et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group Br J Cancer 90 11 2004 2112 2117
64. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 19 2007 2811 2818
65. W. Meier, A. du Bois, A. Reuss, W. Kuhn, S. Olbricht, and M. Gropp et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) Gynecol Oncol 114 2 2009 199 205
66. I. Vergote, N. Finkler, J. del Campo, A. Lohr, J. Hunter, and D. Matei et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer Eur J Cancer 45 13 2009 2324 2332
67. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 19 2010 3107 3114
68. N. Colombo, E. Kutarska, M. Dimopoulos, D.S. Bae, I. Rzepka-Gorska, and M. Bidzinski et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer J Clin Oncol 30 31 2012 3841 3847
69. C. Fotopoulou, I. Vergote, P. Mainwaring, M. Bidzinski, J.B. Vermorken, and S.A. Ghamande et al. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study (published online ahead of print Dec 10, 2013) Ann Oncol 2013 http://dx.doi.org/10.1093/ annonc/mdt515
70. R.W. Naumann, R. Coleman, C. Burger, E.A. Sausville, E. Kutarska, and S.A. Ghamande et al. PRECEDENT: A randomised phase II trial comparing Vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer J Clin Oncol 31 35 2013 4400 4408